Our Journey

Hilleman Laboratories has established a legacy of research excellence in the first decade. The next stage of evolution sees an expansion of its global footprint and significant transformative capabilities. With focus on expansion and growth, Hilleman has moved its global headquarters to Singapore and established its vaccine and biologics R&D and manufacturing hub.


Expected completion of cGMP plant in Singapore


Inauguration of R&D Labs and groundbreaking of pilot cGMP plant in Singapore

Hilleman launches first ever training programme on technology transfer for DCVMN


Hilleman expands global footprint with its new global headquarters in Singapore


Hilleman partners with Bharat Biotech for the development and manufacture of the oral cholera vaccine Hillchol®


Cholera vaccine proceeds to Phase ll trials, with two other assets in development


Hilleman begins developing a high impact cholera vaccine


MSD & Wellcome Trust open R&D facility in Jamia Hamdard University, New Delhi, India